ZYBERNO
Stock Report
Updated Aug 30, 2026

LARIMAR THERAPEUTICS, INC. (LRMR)

Healthcare • NASDAQ

$4.01

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
LARIMAR THERAPEUTICS, INC. (LRMR) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-137.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-338.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LARIMAR THERAPEUTICS, INC. (LRMR) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.01
Market Cap:$416.57M

Valuation Multiples (2)

P/B Ratio:3.27x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$328.84M

Price Action & Momentum (3)

Momentum Percentile:46 / 100
% of 52-Week High:62.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-97.7%
Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-0.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$44.62
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-184.5%
Latest Earnings Filed:2025-11-05
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.70x
Quick Ratio:4.70x
Cash Ratio:2.71x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:126,506,000.00
Cash And Cash Equivalents:92,687,000.00
Long Term Debt:$3.75M
Net Debt:-$87.73M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$178.99M

Bottom Line Performance (3)

-$172.61M
Income Before Tax:-$165.67M
Ebitda Ttm:-178,746,000.00

Operating Expenses (5)

Operating Expenses:178,985,000.00
R And D Expense:157,335,000.00
Sga Expense:21,650,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$165.30M
Current Assets:$160.67M
Ppe Net:2,658,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:37,920,000.00
Current Liabilities:34,166,000.00
Long Term Debt:$3.75M
Short Term Debt:$1.20M

Equity & Capital (3)

Equity:$127.38M
Retained Earnings:-$497.23M
Common Stock:215,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:25,367,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,149,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$113.20M-$113.29M

Investment Activities (2)

Investing Cash Flow:$29.00M
Capital Expenditures Ttm:91,000.00

Financing Activities (3)

Financing Cash Flow:$108.12M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:108,101,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:239,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.95
-$1.95
Earnings Per Share Ttm:-$1.66

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.09

Book Value & Capital (2)

Book Value Per Share:$1.23
Cash Per Share:0.89

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-0.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):16.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:LRMR
Company Name:LARIMAR THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:103.88M
Shares Outstanding Basic:103.88M
Shares Outstanding Diluted:78.32M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 20:58:28 UTC
Data Timestamp:2026-08-17T23:06:17.728313
Scroll to Top